The global travel vaccines market size was worth US$ 4.9 Billion in 2018. Travel vaccines, also known as travel immunizations, are vaccines travelers can get before they visit certain regions across the globe which help protect them from serious diseases. Travel vaccines work by exposing the body to a microorganism or parts of the microorganism of the disease it will protect against. The body responds to the vaccination by making antibodies that will protect it against a situation where there is an exposure to the disease in the future.The global travel vaccines market was worth US$ 4.9 Billion in 2018. Travel vaccines, also known as travel immunizations, are vaccines travelers need before they visit certain regions across the globe due to the potential infection threat in the country or part of that country. These vaccines work by exposing the body to a microorganism or parts of the microorganism of the disease it will protect against. The body responds to the vaccine by making antibodies that will protect it against the disease in the future.
The number of international tourist arrivals worldwide increased from 1.0 Billion in 2012 to nearly 1.4 Billion in 2018. A significant number of these travelers journey from developed countries to regions with endemic diseases. As more people travel to countries with endemic diseases, the demand for vaccines will continue to increase. Moreover, regulatory authorities across the globe have also mandated that travelers should be vaccinated before traveling to disease-prone regions. As a result, travel vaccines have now become an essential requirement in an international travelers list. For instance, the Ministry of Health in the Kingdom of Saudi Arabia requires that all travelers arriving for Hajj and Umrah from countries or areas at risk of diseases such as yellow fever, Meningococcal meningitis and Poliomyelitis must present a valid vaccination certificate. Other factors driving the demand for travel vaccines include increasing awareness levels, technological advancements and increasing incidence of life-threatening infectious diseases. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2024, exhibiting a CAGR of 6.4% during 2019-2024.
Breakup by Composition:
Combination vaccines currently account for the majority of the market share as they are given to travelers in order to protect against multiple diseases.
Breakup by Disease:
Amongst these, hepatitis A represents the largest disease, dominating the market. It is a viral disease that can be transmitted through direct contact with an infectious person or the consumption of contaminated food and water.
On the geographical front, North America enjoys the leading position in the market. A large number of companies in the region are introducing a superior range of travel vaccines, including a vaccine against varicella.
The market is concentrated in nature with the presence of a handful of manufacturers who compete in terms of prices and quality. Some of the leading players operating in the market are:
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at